ERBB2 and breast cancer: Taken together, our results support the notion that calcitriol suppresses both PI3K/AKT and MAPK/ERK pathways in HER2-positive breast cancer cells, thereby reinforcing its potential as an adjuvant agent in combinatorial therapeutic strategies aimed at improving treatment outcomes and overcoming resistance.